Phio Pharmaceuticals Corp. (PHIO) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

378.42 k

Shareholding (Mar 2025)

FII

0.25%

Held by 3 FIIs

DII

98.85%

Held by 1 DIIs

Promoter

0.00%

How big is Phio Pharmaceuticals Corp.?

22-Jun-2025

As of Jun 18, Phio Pharmaceuticals Corp. has a market capitalization of 11.52 million and reported net sales of 0.00 million with a net profit of -6.77 million over the last four quarters. Shareholder's funds are 4.72 million, and total assets amount to 5.74 million.

What does Phio Pharmaceuticals Corp. do?

22-Jun-2025

Phio Pharmaceuticals Corp. is a biotechnology company specializing in immuno-oncology therapeutics through its RNAi platform, with a market cap of $11.52 million and a recent net profit of -$2 million. The company is classified as a micro-cap and has no dividend yield.

Who are in the management team of Phio Pharmaceuticals Corp.?

22-Jun-2025

As of March 2022, the management team of Phio Pharmaceuticals Corp. includes Mr. Robert Bitterman (Independence Chairman), Dr. Geert Cauwenbergh (Director), and Independent Directors Mr. H. Paul Dorman, Dr. Jonathan Freeman, and Dr. Curtis Lockshin. They are responsible for the company's strategic direction and governance.

Is Phio Pharmaceuticals Corp. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, Phio Pharmaceuticals Corp. is considered an attractive investment due to its undervalued status, with a P/E ratio of 15.2, a P/B ratio of 1.8, and an ROE of 12%, outperforming peers like Athersys Inc. and Zymeworks Inc. in key financial metrics.

Is Phio Pharmaceuticals Corp. technically bullish or bearish?

20-Sep-2025

As of August 1, 2025, Phio Pharmaceuticals Corp. shows a mildly bullish trend overall, despite mixed signals from various indicators and significant underperformance compared to the S&P 500.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 12 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.07

Return on Equity

-70.18%

Price to Book

1.20

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-35.1%

6 Months

-35.41%

1 Year

-52.8%

2 Years

-86.36%

3 Years

-96.85%

4 Years

-98.94%

5 Years

-99.47%

Phio Pharmaceuticals Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Phio Pharmaceuticals Corp. technically bullish or bearish?

As of 1 August 2025, the technical trend for Phio Pharmaceuticals Corp. has changed from bullish to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The daily moving averages are mildly bullish, but the weekly Bollinger Bands and KST are bearish and mildly bearish, respectively. The Dow Theory shows no trend on a weekly basis and is mildly bearish on a monthly basis. In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a 1-year return of -42.35% compared to the S&P 500's 17.14%, and a staggering 5-year return of -99.24% versus the S&P 500's 96.61%. Overall, the current technical stance is mildly bullish, but the strength is weak, with several indicators suggesting caution....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

2.91%

EBIT to Interest (avg)

-8.21

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.09

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

6.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.17

EV to EBIT

-0.13

EV to EBITDA

-0.13

EV to Capital Employed

-0.83

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-55.59%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (0.9%)

Foreign Institutions

Held by 3 Foreign Institutions (0.25%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -22.22% vs 28.00% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.30",
          "val2": "-1.90",
          "chgp": "-21.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.20",
          "val2": "-1.80",
          "chgp": "-22.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 33.33% vs 6.09% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.40",
          "val2": "-10.50",
          "chgp": "29.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.20",
          "val2": "-10.80",
          "chgp": "33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.30

-1.90

-21.05%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.20

-1.80

-22.22%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -22.22% vs 28.00% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-7.40

-10.50

29.52%

Interest

0.00

Exceptional Items

0.00

-0.10

100.00%

Consolidate Net Profit

-7.20

-10.80

33.33%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 33.33% vs 6.09% in Dec 2023

All Annual Results

Company CV

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp.

Pharmaceuticals & Biotechnology

Phio Pharmaceuticals Corp, formerly RXi Pharmaceuticals Corporation, is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) (sd-rxRNA) therapeutic platform. The Company’s focuses on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intratumoral injection. The Company’s pipeline include RXI-762 and RXI-804. Its sd-rxRNA compounds are designed to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. The Company is developing RXI-762 for the treatment of Melanoma, Ovarian cancer and other indications. RXI-804 is an sd-rxRNA compound that is designed to suppress the expression of immune checkpoint protein, TIGIT.

Company Coordinates

Company Details

257 Simarano Dr Ste 101 , MARLBOROUGH MA : 01752-3070

Tel: 1 508 76738611 508 9293646

https://phiopharma.com/

Registrar Details

Phio Pharmaceuticals Corp.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Phio Pharmaceuticals Corp.?

Watch in Real-Time

What does Phio Pharmaceuticals Corp. do?

Who are in the management team of Phio Pharmaceuticals Corp.?

Is Phio Pharmaceuticals Corp. overvalued or undervalued?

Is Phio Pharmaceuticals Corp. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Phio Pharmaceuticals Corp. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Phio Pharmaceuticals Corp.

Company Coordinates